ASCO® 2024 Highlights: Presenter Vignette – Toshinari Yamashita

Dr. Toshinari Yamashita

Toshinari Yamashita

MD, PhD

Kanagawa Cancer Center

Abstract# 1007

Trastuzumab and pertuzumab in combination with eribulin mesylate or a taxane as first-line chemotherapeutic treatment for HER2-positive, locally advanced or metastatic breast cancer: Results of a multicenter, randomized, non-inferiority phase 3 trial in Japan (JBCRG-M06/EMERALD).